

**From:** [Funk, Andrew \[IBPE\]](#)  
**To:** [Jorgenson, Debbie \[IBPE\]](#)  
**Subject:** FW: DEA Eases Requirements for FDA-Approved Clinical Trials on Cannabidiol  
**Date:** Saturday, December 26, 2015 6:40:52 PM

---

Debbie,

Will you add this press-release from the DEA to Board Books as an FYI?

Thanks,

Andrew Funk, Pharm.D.  
Executive Director  
Iowa Board of Pharmacy  
RiverPoint Business Park  
400 SW 8th Street, Suite E  
Des Moines, Iowa 50309-4688  
515.281.5944 Main Line  
[andrew.funk@iowa.gov](mailto:andrew.funk@iowa.gov)

---

**From:** Andrew Funk [aa\_funk51804@yahoo.com]  
**Sent:** Friday, December 25, 2015 9:22 PM  
**To:** Funk, Andrew [IBPE]  
**Subject:** Fw: DEA Eases Requirements for FDA-Approved Clinical Trials on Cannabidiol

On Wednesday, December 23, 2015 9:31 AM, U.S. Drug Enforcement Administration <[dea@public.govdelivery.com](mailto:dea@public.govdelivery.com)> wrote:

banner



**FOR IMMEDIATE RELEASE**

**Contact: DEA Public Affairs**

**(202) 307-7977**

## Press Release

### **DEA Eases Requirements for FDA-Approved Clinical Trials on Cannabidiol**

**DEC 23 - (Washington, D.C.)** – The United States Drug Enforcement Administration (DEA) recently eased some of the regulatory requirements imposed by the [Controlled Substances Act \(CSA\)](#) for those who are conducting Food and Drug Administration-approved clinical trials on cannabidiol (CBD), an extract of the marijuana plant. These modifications will streamline the research process regarding CBD's possible medicinal value and help foster ongoing scientific studies. The DEA notified affected researchers by letter of the changes, which take effect immediately.

Federal Regulation [21 CFR 1301.18](#) requires researchers conducting CBD-based clinical trials under an [FDA Investigational New Drug Application](#) to have a DEA research registration. This registration permits the possession of an approved amount of CBD for a specific research protocol. Prior to now, researchers who expanded the scope of their studies and needed more CBD than they were initially approved for had to request, in writing, a modification to their DEA research registrations – potentially delaying that research while the modification underwent an approval process that includes both the DEA and the FDA. Under these changes, a previously registered CBD clinical researcher who is granted a waiver can readily modify their protocol and continue their research seamlessly. This waiver effectively removes a step from the approval process.

Marijuana is a [Schedule I](#) controlled substance because of the presence of [tetrahydrocannabinol \(THC\)](#), marijuana's psychoactive ingredient. Because CBD contains less than 1 percent THC and has shown some potential medicinal value, there is great interest in studying it for medical applications. Currently, CBD is a Schedule I controlled substance as defined under the CSA.

Though the FDA approves drugs for medical use in the United States, the DEA regulates the handling of all controlled substances, including those being used by researchers to conduct studies.

###

---

You have received this e-mail because you have asked to be notified of changes to the U.S. Department of Justice Web site. Update your subscription to this service, modify your password or e-mail address, or stop subscriptions at any time on your [Subscriber Preferences Page](#). You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact [subscriberhelp.govdelivery.com](#). If you have questions about the Department of Justice Web site, please contact [webmaster@usdoj.gov](#). GovDelivery is providing this service on behalf of the Department of Justice and may not use your subscription information for any other purposes.

[Department of Justice Privacy Policy](#)

[GovDelivery Privacy Policy](#)

This email was sent to aa\_funk51804@yahoo.com using GovDelivery, on behalf of: U.S. Drug Enforcement Administration · 950 Pennsylvania Ave., NW · Washington, DC 20530 · 800-439-1420